EC approval for bevacizumab biosimilar Alymsys/Oyavas

Biosimilars/News | Posted 23/04/2021 post-comment0 Post your comment

The European Commission (EC) granted marketing authorization for the bevacizumab biosimilar Alymsys/Oyavas (MB02), on 31 March 2021. The biosimilar is developed by mAbxience, a biopharmaceutical firm with offices in Spain, Argentina and Switzerland.

Cancer Cell V13I20

After receiving marketing authorization from the EC, mAbxience’s bevacizumab biosimilar has launched in Germany and The Netherlands, where it is marketed by STADA, with other countries soon to follow.

Bevacizumab is a humanized monoclonal antibody treatment for a number of cancers, as well as age-related macular degeneration. It inhibits angiogenesis (the formation of new blood vessels) by blocking the action of vascular endothelial growth factor A (VEGF-A). Bevacizumab can therefore slow the growth of new blood vessels in tumours and is used to treat various cancers including colorectal, lung, breast, glioblastoma, kidney and ovarian cancers. The originator product, Avastin, is sold by Roche/Genentech.

The approval of mAbxience’s biosimilar by the EC follows the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) positive recommendation at its meetings held 25–29 January 2021 [1]. MB02 received a positive opinion for the treatment of carcinoma of the colon or rectum, breast cancer, non-small cell lung cancer, renal cell cancer, epithelial ovarian, fallopian tube or primary peritoneal cancer and carcinoma of the cervix.

Now that the biosimilar has received marketing authorization from the EC, it can be commercialized (under the trade names Alymsys® and Oyavas®) and sold by German pharmaceutical giant STADA. Under the terms of the agreement between mAbxience and STADA, STADA holds the marketing authorization and sales and marketing rights in 40 European countries, including all members of the EU-27.

Emmanuelle Lepine, General Manager at mAbxience, commented: ‘The launch of our Bevacizumab under the trademarks Alymsys® and Oyavas® in the European market will be a perfect example of how innovation and cutting-edge R & D technology can be applied to obtain a high quality, affordable medicine which, as well as providing alternatives for the healthcare system, will also improve patient access to costly treatments’.

STADA has already launched the product on the market in Germany and The Netherlands. They say the product will launch in other European countries soon, depending on national pricing and reimbursement clearance. CEO of STADA, Peter Goldschmidt, said: ‘Introducing the new biosimilar is testament to STADA’s strategy of being a go-to-partner for enabling patient access to biosimilars in Europe’.

EMA also recently recommended the approval of two bevacizumab biosimilars, Abevmy and Lextemy, produced by Mylan (now Viatris) [1], bringing the total number of bevacizumab biosimilars to be approved in Europe to 73 [2]. EMA recommended approval of Samsung Bioepis bevacizumab biosimilar, Onbevzi, in November 2020 [3].

Related articles
Argentina approves bevacizumab similar biological medicine Zutrab

Biosimilars applications under review by EMA – January 2021

Biosimilars of bevacizumab

LATIN AMERICAN FORUM – Coming soon!

To further enhance the objectives of GaBI in sharing information and knowledge that ensure policies supportive of safe biosimilars use, we are pleased to announce that we will be launching a new section on GaBI Online and GaBI Journal, the ‘Latin American Forum’ (in Spanish) featuring the latest news and updates on research and developments in generic and biosimilar medicines in Latin America.

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.

 

LATIN AMERICAN FORUM – Próximamente!

Para fomentar los objetivos de GaBI sobre la difusión de información y conocimiento sobre las políticas de apoyo que garantizan el uso seguro de medicamentos biosimilares, nos complace anunciar el lanzamiento de una nueva sección en GaBI Online y GaBI Journal, el ‘Latin American Forum’ (en español), que presentará las últimas noticias y actualizaciones en investigación y desarrollo sobre medicamentos genéricos y biosimilares en Latinoamérica.

Regístrese para recibir el boletín informativo GaBI Latin American Forum. Informe a colegas y amigos sobre esta nueva iniciativa. 

References
1. GaBI Online - Generics and Biosimilars Initiative. EMA recommends approval of four bevacizumab biosimilars [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Apr 23]. Available from: www.gabionline.net/Biosimilars/News/EMA-recommends-approval-of-four-bevacizumab-biosimilars 
2. GaBI Online - Generics and Biosimilars Initiative. Biosimilars approved in Europe [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Apr 23]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-Europe 
3. GaBI Online - Generics and Biosimilars Initiative. EMA recommends approval of bevacizumab biosimilar Onbevzi [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Apr 23]. Available from: www.gabionline.net/Biosimilars/News/EMA-recommends-approval-of-bevacizumab-biosimilar-Onbevzi

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2021 Pro Pharma Communications International. All Rights Reserved.

Source: mAbxience; STADA

comment icon Comments (0)
Post your comment
Related content
EMA recommends approval of two adalimumab biosimilars
ST002293
Biosimilars/News Posted 01/10/2021
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010